Literature DB >> 26203597

Fructose and liver function--is this behind nonalcoholic liver disease?

Ran Jin1, Miriam B Vos.   

Abstract

PURPOSE OF REVIEW: The purpose was to summarize recent advances in the understanding of nonalcoholic fatty liver disease (NAFLD) pathophysiology and the role of fructose in NAFLD. RECENT
FINDINGS: Epidemiological studies continue to point to a strong association between high fructose intake and NAFLD and its severity. New studies of NAFLD reveal the importance of upregulated de novo lipogenesis as a key feature in its pathophysiology along with increased visceral adiposity and alteration of gut microbiome. Studies of fructose in NAFLD show how this nutrient may uniquely exacerbate the phenotype of NAFLD. The timing of exposure to fructose may be important with early (in utero) exposure being particularly harmful.
SUMMARY: Fructose is a potentially modifiable environmental exposure that appears to exacerbate NAFLD through multiple mechanisms. Although larger, longer clinical studies are still needed, it appears that limitation of fructose sources in the diet is beneficial in NAFLD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26203597     DOI: 10.1097/MCO.0000000000000203

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  7 in total

1.  Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice.

Authors:  Maria Elizabeth de Sousa Rodrigues; Mandakh Bekhbat; Madelyn C Houser; Jianjun Chang; Douglas I Walker; Dean P Jones; Claudia M P Oller do Nascimento; Christopher J Barnum; Malú G Tansey
Journal:  Brain Behav Immun       Date:  2016-09-02       Impact factor: 7.217

2.  Product Control and Insight into Conversion of C6 Aldose Toward C2, C4 and C6 Alditols in One-Pot Retro-Aldol Condensation and Hydrogenation Processes.

Authors:  Yingshuang Hui; Yulu Zhan; Wenrong Hou; Lou Gao; Yahong Zhang; Yi Tang
Journal:  ChemistryOpen       Date:  2021-05       Impact factor: 2.630

3.  Early Effects of a Low Fat, Fructose-Rich Diet on Liver Metabolism, Insulin Signaling, and Oxidative Stress in Young and Adult Rats.

Authors:  Raffaella Crescenzo; Luisa Cigliano; Arianna Mazzoli; Rosa Cancelliere; Rosa Carotenuto; Margherita Tussellino; Giovanna Liverini; Susanna Iossa
Journal:  Front Physiol       Date:  2018-04-26       Impact factor: 4.566

4.  Uncaria tomentosa improves insulin sensitivity and inflammation in experimental NAFLD.

Authors:  Layanne C C Araujo; Karla B Feitosa; Gilson M Murata; Isadora C Furigo; Simone A Teixeira; Camila F Lucena; Luciene M Ribeiro; Marcelo N Muscará; Soraia K P Costa; José Donato; Silvana Bordin; Rui Curi; Carla R O Carvalho
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

5.  Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.

Authors:  Cuiqing Zhao; Liming Liu; Qi Liu; Fengyuan Li; Lihua Zhang; Fenxia Zhu; Tuo Shao; Shirish Barve; Yiping Chen; Xiaokun Li; Craig J McClain; Wenke Feng
Journal:  Mol Metab       Date:  2019-09-03       Impact factor: 7.422

Review 6.  Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.

Authors:  Gigliola Alberti; Juan Cristóbal Gana; José L Santos
Journal:  Nutrients       Date:  2020-11-17       Impact factor: 5.717

7.  Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults.

Authors:  Desiree M Sigala; Bettina Hieronimus; Valentina Medici; Vivien Lee; Marinelle V Nunez; Andrew A Bremer; Chad L Cox; Candice A Price; Yanet Benyam; Abhijit J Chaudhari; Yasser Abdelhafez; John P McGahan; Michael I Goran; Claude B Sirlin; Giovanni Pacini; Andrea Tura; Nancy L Keim; Peter J Havel; Kimber L Stanhope
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.